Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
plitidepsin + bortezomib + dexamethasone
- Development stage
- Discontinued
- Lead developer
- PharmaMar
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Peptides
- Administration
- Intravenous (plitidepsin), Subcutaneous (bortezomib), Oral (dexamethasone)
01
Overview
**Plitidepsin + bortezomib + dexamethasone** is an investigational antineoplastic combination regimen being studied primarily in relapsed and/or refractory multiple myeloma. Plitidepsin is a marine-derived cyclic peptide that induces apoptosis in tumor cells by binding to eEF1A2 and interfering with protein synthesis. Bortezomib is a proteasome inhibitor that disrupts proteasomal-mediated protein degradation, leading to apoptosis of cancer cells. Dexamethasone is a synthetic glucocorticoid with anti-inflammatory and antineoplastic properties, inducing apoptosis in certain hematologic malignancies. The combination is developed for synergistic cytotoxicity in multiple myeloma. Clinical studies have shown this triple regimen to have an acceptable safety profile and moderate antitumor activity in heavily pretreated relapsed/refractory multiple myeloma patients. The developer is PharmaMar, with clinical research involving use in patients with disease resistant to standard therapies[1][3][4][5].
- Brand names
- None for the combination
- Other names
- None for the combination
02
Targets
EEF1A2 (Eukaryotic elongation factor 1 alpha 2)GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on plitidepsin + bortezomib + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on plitidepsin + bortezomib + dexamethasone.